Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, July 17, 2019
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Thursday, July 11, 2019
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
Wednesday, July 10, 2019
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
Monday, July 8, 2019
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
Tuesday, June 18, 2019
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
Wednesday, May 29, 2019
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
Friday, May 17, 2019
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
Thursday, May 16, 2019
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: